Skip to main content

Solutions
Expertise
Company
Trials

Contact Us

China
Japan

Solutions
Expertise
Company
Trials

Contact Us

China
Japan

Solutions
Innovations & Therapeutic Expertise
Volunteers, Studies & Investigators
Ecosystem, Education & Careers
News, Events & Resources
About Us
Careers

Solutions
Expertise
Patient Stories
Trials
Resources
News & Events
COVID-19
Company
Careers

China
Japan

Contact Us

Get Personalized Email Content

Global Locations

275 Grove St., Suite 101C, Newton, MA 02466
+1 617 454 9300

2520 Meridian Parkway, Research Triangle Park, Suite 200, Durham, NC 27713
+1 919 544 3170

Solutions Overview
Clinical Development
Outsourcing Services

Parexel^® Biotech
Consulting
The Medical Affairs Company ® (TMAC)
Medical Communications
Real-World Evidence and Late Phase

Solutions by Industry
- Pharma Solutions
- Medical Devices
Solutions by Development Phase

Overview
Patient Centricity
Precision Medicine
Adaptive & Flexible Trials
Real World Evidence
The Innovation Imperative
Our Experts

Therapeutic Areas

Overview
T.J.'s Story
Tina's Story
Dayson & Erika's Story
Paul's Story
Monica's Story

Rob's Story
Yasmeem's Story
Anisha's Story
Sara's Story
Stacy's Story

Trial Volunteer Overview
Investigators
- Clinical Trial Investigator Sign-Up

Global Study Locations

Parexel Resource Center
Parexel Insights Blog
Podcasts
Drug Innovation
Our Experts
Parexel Academy
Your Preferences

Social Channels
- LinkedIn
- Facebook
- Twitter
- YouTube

Parexel Newsroom
Events and Webinars

Long COVID Syndrome Program
COVID-19 Response

COVID-19 Resource Center
COVID Clearinghouse Data Platform

Our Company
Leadership Team
Our DE&I Strategy
- Discussions on Diversity
Suppliers
Careers Overview
- Career Opportunities
Trust & Privacy
Environmental, Social, & Governance (ESG)
External Support Center

Compliance & Ethics
Global Locations
Partners
Contact Us

Careers Overview
- Career Opportunities

Welcome to the Parexel Resource Center

Find the latest resources on regulatory, clinical development, biotech, and more. Browse our content below.

Parexel Resource Center

Recent Searches

Share this Post

Share on facebook
Share on twitter
Share on linkedin
Share on email

Home
Quality & Compliance
Parexel on the pulse

Parexel on the pulse

Parexel regulatory expert, Mark Birse, gives an update on BREXIT.

Previous Flipbook

Impending avalanche of regulatory compliance activity: Are you prepared?
Next Flipbook

Case Study Achieving Product Endorsement after a FDA Warning Letter

Other content in this Stream

Parexel Webinar Regulatory Inspections Post COVID

Parexel expert, Mark Birse, a former MHRA regulator, addresses how the pandemic changed new inspection practices and remote desktop facility assessments. He shares his opinions on the long-term impact

Watch Video
Impending avalanche of regulatory compliance activity: Are you prepared?

Read Flipbook
Compliance Consulting Services Brochure for Law Firms

Read Flipbook
Risk Mitigation and Compliance Consulting Brochure for BioPharma Companies

Read Flipbook
How to interact virtually with health authorities

Read Flipbook
GxP On-Site Inspections are Restarting: Preparing for inspections under the “new normal”

As global regulatory agencies are preparing to return to on-site inspections1, industry needs to be ready. With the continued threat of COVID-19, the way inspections will be performed and hosted...

Read Article
FDA Expectations for Responding to Employees in Pharmaceutical Manufacturing Infected with COVID-19

Global manufacturers and regulators are facing new challenges during the SARS-CoV-2 pandemic to maintain supply chains, and avoid shortages, of drugs, biologics and medical devices. Numerous...

Read Article
Navigating new steps in how FDA is managing COVID-19 Products

Read Article
Biosimilars in the time of COVID-19 and beyond

Introduction The recent COVID-19 pandemic has triggered a race for pharmaceutical companies to repurpose their commercialized drugs approved for other clinical indications to treat patients...

Read Article
Considerations for protecting your business and employees from COVID-19

This assessment highlights some planning considerations to help you maintain business operations, while protecting the safety of employees and customers during this pandemic.

Read Article
Understanding the COVID-19 regulatory procedures the FDA is using

A diagram that shows various procedural steps when interacting with the FDA through CTAP.

Read Article
Restricted pharmaceutical exports from India: Are you ready to mitigate risk of drug shortages?

Read Article
Understanding Department of Justice Enforcement Policies relating to FDA-Regulated Products

At the recent 2019 Enforcement, Litigation and Compliance Conference hosted by the Food and Drug Law Institute (see here), Deputy Assistant Attorney General David Morrell delivered the...

Read Article
What Influences the Compliance Culture at FDA?

The Office of Compliance (OC) in the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration (FDA) is a large organization. It has hundreds of personnel who are...

Read Article
FDA & Nitrosamine Impurities – The Proverb of the King with Long Arms

If the dictionary is to be believed, the expression that kings have long arms was first listed as a proverb in 1539 (see here). Over time it has developed into the commonly recognized idea...

Read Article
As PIC/S expansion continues, what does this mean for manufacturers seeking to join?

Over the last few years the expansion of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) has continued at pace, with more Good Manufacturing Practice (GMP) Inspectorates joining,...

Read Article
It’s Not Just Manufacturing – Drug Development Presents Corporate Compliance Risks Too

In a prior blog post, I wrote about the issue of whether corporate boards of directors could be confronted with the issue of whether they could be held liable for not implementing a...

Read Article
Between Scylla and Charybdis – FDA Revised Draft Guidance on CGMP Compliance for 503(B) Outsourcing Facilities

In January 2020 the Food and Drug Administration (FDA or “agency”) published the revised draft guidance Current Good Manufacturing Practice – Guidance for Human Drug Compounding Outsourcing...

Read Article
Beware of Regional Donor Eligibility Requirements: They're Not Really the Same Everywhere!

Donor Eligibility (DE) determination is a central aspect of how FDA and other regulatory authorities ensure that a product from a single allogeneic donor has acceptable very low risk of...

Read Article
FDA Inspections and Cleaning

Companies often have many questions concerning their approach to cleaning validation when it comes to preparing for an FDA Inspection. Often cleaning validation studies are extensively...

Read Article